Could the right approach help you avoid bigger surgery?

Avoiding the next escalation — an ankle fusion, a knee replacement, or an early hip replacement — usually comes down to one practical question: is the problem a localised cartilage defect that can be supported to heal, or is it widespread arthritis where the joint surface is broadly worn? The answer shapes which joint-preservation option is appropriate, and whether the goal is to support repair or to manage symptoms until a more definitive procedure is unavoidable.

Two distinct pathways sit at the joint-preservation end of that spectrum. The ChondroFiller injection is a non-surgical, ultrasound-guided outpatient procedure: the ChondroFiller scaffold — a CE-marked Class III type I collagen hydrogel — is delivered without theatre, incision, or general anaesthetic, suited to accessible lesions and smaller joints. The Liquid Cartilage procedure is Professor Paul Lee's keyhole surgical protocol: it delivers ChondroFiller arthroscopically, combined with platelet-rich fibrin, platelet-rich plasma, tranexamic acid, and where indicated the patient's own mesenchymal stem cells (from bone-marrow aspirate concentrate or micro-fragmented fat), within a structured peri-operative and rehabilitation programme. These are not synonyms for the same thing; they are different treatment pathways, each suited to a different clinical profile.

Both pathways target symptomatic, focal, full-thickness cartilage lesions in an otherwise reasonably preserved joint, rather than established diffuse osteoarthritis. Independent educational material is explicit that ChondroFiller is not a miracle gel and does not regrow normal hyaline cartilage across established osteoarthritis. A useful way to situate these options in the wider decision pathway is:

• Symptom management — activity modification, physiotherapy, analgesia.
• Biologic or scaffold-based joint preservation — ChondroFiller injection for accessible focal defects; the Liquid Cartilage surgical protocol for larger or load-bearing lesions requiring arthroscopic preparation.
• Surgical cartilage restoration — microfracture, scaffold-augmented techniques, MACI or ACI, osteochondral grafts — when lesion pattern and durability goals justify a more involved procedure.
• Joint replacement (hip or knee) or fusion (ankle) for advanced, diffuse damage where the above options are no longer appropriate.

Evidence for durable joint preservation still comes primarily from established procedures. For knee MACI, long-term follow-up series report sustained improvements and low arthroplasty conversion rates at 10–17 years. For the talus, mid-term talar MACI series show large functional gains maintained to around five years. For injectable and acellular scaffolds, the most relevant evidence covers outcomes to two years; what is not yet shown in joint-specific trials is that these approaches reliably prevent later fusion or replacement. The defensible aim is supporting symptoms and function in carefully defined focal defects while keeping bigger surgery as an option if the joint progresses.

Liquid cartilage for ankle lesions and fusion risk

An osteochondral lesion of the talus is a common focal damage pattern in the ankle after a sprain or impact injury, where a small area of cartilage (sometimes with underlying bone) is disrupted on the top of the talus. In practice this can present as deep ankle pain, swelling after activity, and mechanical symptoms such as catching or giving way — often in younger, active adults rather than in older people with established, widespread ankle arthritis.

For many symptomatic talar osteochondral lesions, the baseline surgical benchmark has been arthroscopic debridement with or without microfracture. In a retrospective comparison published in Frontiers in Surgery (debridement, n=39; microfracture, n=42), both groups improved after surgery, but the microfracture group had significantly larger gains in AOFAS ankle scores and pain VAS than debridement alone. The most favourable results were in younger (aged 30 or under) and lower-BMI male patients. That pattern supports microfracture as more than tidying-up for selected focal talar lesions, while also indicating that patient factors meaningfully influence outcomes.

When the talar defect is deeper, more complex, or has already failed a simpler repair, cell-based matrix techniques have the strongest published ankle-specific results. A prospective MACI series in 22 patients (mean age 23.9 years; mean lesion size 1.94 cm²) reported improvements maintained at around 63.5 months: mean AOFAS scores rose from 70.1 preoperatively to approximately 95, pain VAS fell from 5.7 to 0.9, and MRI MOCART scores improved into the mid-80s by final follow-up. Most clinical improvement occurred within the first 12 months and then remained stable through the five-year mark — a useful durability signal for joint-preservation planning in the talus.

Against that backdrop, a scaffold-based approach — whether via the ChondroFiller injection for accessible smaller lesions or the Liquid Cartilage surgical protocol for defects requiring arthroscopic preparation — is best understood as a way to support repair in a focal talar defect without committing to a two-stage, cell-expansion pathway. The collagen scaffold aims to fill and stabilise the defect and provide a temporary matrix that may encourage the body's own cells to populate the area, rather than simply smoothing the surface as in debridement. This sits closer to the logic of matrix-assisted repair than to pain-relief injections, but it is still intended for discrete lesions rather than for an ankle where the joint surface is broadly worn.

The key practical limitation is that ankle-specific clinical evidence for collagen scaffolds remains thinner than for microfracture and talar MACI. Independent clinical education materials are clear that ChondroFiller is not positioned to regenerate normal hyaline cartilage across established osteoarthritis and has limited published ankle-specific outcome series — which matters when trying to answer hard end points such as fewer repeat arthroscopies or avoiding fusion.

Ankle fusion (tibiotalar arthrodesis) is generally considered later in the pathway, when pain and loss of function are driven by advanced, often diffuse joint surface damage rather than by a single contained lesion. In that setting, a focal scaffold treatment is unlikely to change the underlying mechanical reality that the joint surface is globally compromised.

Knee defects moving beyond microfracture alone

Knee cartilage repair most often comes up in active adults in their 20s to 50s who have a contained, symptomatic defect on the femoral condyle or trochlea — often in the 1–7 cm² range — rather than established, widespread tricompartmental osteoarthritis. The day-to-day problem is swelling after sport, sharp pain on stairs or squatting, and occasional catching or locking, with an MRI report describing a focal full-thickness lesion rather than bone-on-bone change.

Microfracture became popular because it is a single keyhole operation and, for smaller defects, can deliver a short-term improvement in pain and function. The principle is marrow stimulation: small perforations are made in the subchondral bone so marrow cells and growth factors can enter the defect and form a repair clot. The trade-off is that the repair tissue is typically fibrocartilage rather than the organised hyaline cartilage found in a healthy joint surface, and concerns remain about durability and the effect on the subchondral bone plate.

The best summary of how microfracture compares with microfracture plus scaffold in the modern knee literature comes from a 2024 systematic review and meta-analysis of 10 randomised controlled trials (378 patients). When outcomes were pooled at 12 and 24 months, scaffold-augmented approaches did not show a statistically significant overall advantage over microfracture alone across IKDC and KOOS function scores, pain VAS, and MRI MOCART assessments. The same review highlighted a recurring pattern in longer follow-up: microfracture improvements can fade after the early period, and some individual longer-term trials have favoured adding a scaffold, even if that signal is not consistent across all studies at one to two years.

One reason the field has moved beyond microfracture alone is that there are scaffold technologies with randomised evidence of better early clinical outcomes than standard care. In a multicentre RCT involving 251 adults across 26 centres, a cell-free, off-the-shelf aragonite-based scaffold was compared with surgeon's choice standard care (debridement or microfracture) for 1–7 cm² cartilage lesions. The two-year analysis reported superior clinical outcomes in the scaffold arm, and the subsequent five-year follow-up addressed durability, treatment failure, and whether patients progressed to bigger operations.

In the context of LCC's own practice, the Liquid Cartilage surgical protocol occupies this scaffold-based space for the knee: arthroscopic preparation of the defect, placement of ChondroFiller under dry CO₂ insufflation, and biological augmentation with platelet-rich fibrin, platelet-rich plasma, tranexamic acid, and where indicated mesenchymal stem cells from bone-marrow aspirate concentrate or micro-fragmented fat. This is genuine keyhole surgery — theatre, anaesthetic, and a structured rehabilitation programme over months — not an outpatient injection. For accessible knee lesions where surgical preparation is not required, the ChondroFiller injection as a non-surgical outpatient procedure may be considered for selected patients; the clinical presentation and defect characteristics determine which pathway is appropriate.

The main decision shift is not that any scaffold approach has already proven superiority over microfracture in the knee across every RCT. It is that focal knee defects are increasingly framed as a scaffold or restoration problem rather than a drill-a-few-holes problem. In that framing, scaffold-based approaches — whether surgical or injection-led — are most directly competing with debridement and microfracture for contained defects, aiming for symptom and function improvement over the first one to two years while trying to preserve better options if further surgery is needed. Joint replacement remains a separate pathway for diffuse, end-stage disease rather than isolated focal lesions.

Cartilage transplantation versus two-stage MACI: where each fits

The most useful way to keep cartilage transplantation claims in proportion is to set a clear benchmark first. The comparison below uses two-stage MACI in the knee as the reference standard for cell-based restoration, then shows what has and has not translated convincingly to the ankle.

Two-stage MACI in the knee: the long-term benchmark

In the knee, MACI is a two-stage pathway: an initial arthroscopy to take a small cartilage biopsy, laboratory expansion of chondrocytes and seeding onto a collagen membrane, and then a second operation to implant the cell-seeded matrix. That two-step structure is the main trade-off for the best-documented durability signal in cartilage restoration.

Long-term follow-up is one of MACI's strongest features in the knee literature. A systematic review with minimum 10-year follow-up (168 patients; 188 tibiofemoral defects) reported sustained improvements in patient-reported outcomes, generally satisfactory defect fill on MRI, a 9.0% all-cause reoperation rate, and 7.4% progression to total knee arthroplasty over 10–17 years. That kind of horizon is unusual in cartilage repair, and it frames why knee MACI is often treated as a durability benchmark rather than simply a symptom-relief procedure.

Across a broader evidence base, a meta-analysis covering 47 studies (1,993 patients) found that several reconstructive strategies — ACI/MACI, osteochondral autograft transfer, and osteochondral allograft — each produced significant improvements in knee pain and function scores. Technique choice depends on defect characteristics and patient factors rather than one method being universally best.

When cell-based methods move to the ankle: encouraging, but a shorter runway

In the talus, MACI has been adapted for selected deep osteochondral lesions, and the published outcomes are best read as promising mid-term ankle preservation rather than the decades-long track record seen in knee MACI. A prospective talus MACI series of 22 patients (mean age 23.9 years; mean lesion 1.94 cm²) reported large functional gains with follow-up to around 63.5 months, with most improvement in the first postoperative year and stability thereafter.

That difference in runway — about five years in the talus series versus 10–17 years in knee MACI reviews — helps explain why ankle cartilage transplantation can sound more established online than it actually is in published comparative terms. The ankle data are real and clinically useful, but they are not yet a like-for-like substitute for the depth of knee MACI follow-up.

HD-ACI: an evolution of MACI, not a true single-stage solution

High-density ACI is often presented as next-generation because it increases cell seeding density (reported at around 5 million chondrocytes per cm² on a membrane) and has produced more hyaline-like repair cartilage than lower-density approaches in preclinical work. Clinically it has been used for knee and ankle defects. However, HD-ACI still relies on ex vivo cell expansion and therefore retains the core MACI trade-off: it remains a cell-dependent, theatre-based, multi-step pathway, and published clinical outcome data are described as relatively limited compared with the established long-term knee MACI literature.

Single-treatment ACI (STACI): feasible in one operation, but mostly knee-focused and early

True single-stage ACI-style approaches aim to avoid the two-stage burden by doing harvesting and processing during one operation. A reported single-surgery co-implantation technique processed a cartilage biopsy and bone marrow aspirate intraoperatively (around 100 minutes) and implanted a mixed cell population at a standardised dose of roughly 9 million cells per cm², across 141 patients with lesions averaging 4.0 cm². The publication is primarily a feasibility account — tissue inputs, cell yields, and operating-room logistics — rather than robust long-term head-to-head outcomes, and the clinical experience is mainly in the knee rather than the talus. Single-treatment ACI for the ankle remains emerging: the concept is clear, but ankle-specific outcome evidence is thin compared with established two-stage ankle MACI series.

Where ChondroFiller injection and Liquid Cartilage fit beside these operative benchmarks

The operative pathways described above — MACI, HD-ACI, and early STACI-style approaches — share a defining feature: they are cell-based restoration strategies built around surgical defect preparation and the handling of living cells. The two LCC scaffold-based pathways differ from one another as well as from these cell-based options.

The ChondroFiller injection is a non-surgical, ultrasound-guided outpatient procedure. ChondroFiller, the CE-marked Class III acellular collagen hydrogel (Meidrix Biomedicals, Germany), is delivered without theatre, incision, or anaesthetic. It is suited to accessible lesions where direct arthroscopic preparation is not required and where the treatment burden of surgery is a relevant consideration.

The Liquid Cartilage procedure is Professor Lee's keyhole surgical protocol: arthroscopic preparation, ChondroFiller placement under dry CO₂ insufflation, biological augmentation with platelet-rich fibrin, platelet-rich plasma, tranexamic acid, and optionally mesenchymal stem cells from bone-marrow aspirate concentrate or micro-fragmented fat. It is genuine surgery — theatre, anaesthetic, tourniquet, a structured peri-operative regimen including intravenous vitamins B and C, and a rehabilitation programme extending over months. For larger or load-bearing defects where thorough preparation of the defect floor and biological environment is likely to improve outcomes, this surgical protocol is the appropriate pathway.

Both sit conceptually as joint-preservation bridges — lower treatment burden than two-stage cell-based approaches, no biopsy or laboratory expansion required — while the cell-based options remain the benchmark when the priority is the most established long-term restorative evidence. CE marking and the published clinical outcome data (IKDC improvement of approximately 30 points over 12–36 months in the knee; modified Harris Hip Score improvement of over 30 points in the hip; MOCART scores consistently around 80 and above) belong to ChondroFiller the device, and reflect results achieved in both surgical and injection-led settings.

Who hip Liquid Cartilage surgery might suit instead of early replacement

Painful hip cartilage damage does not always mean a hip replacement is the next step. The common hip preservation scenario is a mechanically driven problem — often femoroacetabular impingement with a labral tear — where a discrete area of cartilage has failed (a focal full-thickness defect), but the rest of the joint still has enough cartilage cover that it is not yet behaving like end-stage arthritis on imaging. In clinical terms this tends to show up in active adults, often with pain provoked by hip flexion and rotation, such as deep sitting, twisting in sport, or getting in and out of a car.

Where the Liquid Cartilage protocol fits in hip preservation

In the peer-reviewed hip arthroscopy literature, ChondroFiller is described as a cell-free collagen matrix used as a one-step adjunct when a surgeon encounters a symptomatic full-thickness chondral defect during hip arthroscopy. A 2021 technique report (the needle and curette technique) sets it firmly in that context: defect preparation, then delivery of the collagen gel directly into the contained lesion under arthroscopic visualisation. Microfracture is described as the standard approach for small focal hip lesions, but the usual concern is that microfracture produces fibrocartilage with variable durability beyond about two to three years — one reason biological scaffolds are being explored in the hip.

In LCC's surgical practice, this is where the Liquid Cartilage protocol is used: a keyhole procedure in which ChondroFiller is placed arthroscopically alongside biological adjuncts (platelet-rich fibrin, platelet-rich plasma, tranexamic acid, and optionally mesenchymal stem cells), typically in the same operation as labral repair or reconstruction and correction of the femoroacetabular impingement bony mechanics. The target is a pothole, not a worn-out road. Published work in this area is weighted towards technique and defect preparation rather than robust long-term comparative data versus microfracture or arthroplasty.

A biological scaffold with defined limits

The biological plaster framing used in some hip-focused educational material — stabilising a local defect, filling it neatly, and providing a temporary scaffold to support repair — is consistent with how surgeons describe collagen matrices in focal defect work. Independent clinical education material is clear about the boundaries: ChondroFiller is not a miracle gel, is not positioned as a non-surgical cure for arthritis, and does not regrow normal hyaline cartilage across an arthritic joint. It is described as an acellular scaffold for surgically accessed focal defects, with limited published clinical evidence — language that narrows candidacy away from established osteoarthritis and towards contained lesions in otherwise reasonably preserved joints.

How this differs from the usual hip replacement threshold

NHS guidance frames total hip replacement around severe hip pain and disability, most often from arthritis or significant joint damage, where symptoms persist despite conservative measures (pain relief, physiotherapy, walking aids) and where daily life and mobility are substantially affected. That picture usually corresponds to diffuse cartilage loss and joint-space narrowing rather than a single contained defect — so it is typically beyond what any focal scaffold approach is designed to address.

In practice, the dividing line is less about a brand name and more about the pattern of disease on MRI or X-ray: a focal, symptomatic defect in a relatively preserved hip may sit in the joint-preservation lane — often alongside treatment of femoroacetabular impingement and labral pathology — whereas a hip that is globally worn, especially when pain affects sleep and basic walking, more often meets the replacement indications.

Planning your next steps with a cartilage specialist

A sensible plan usually starts with clarifying whether symptoms are being driven by a contained focal defect or by diffuse osteoarthritis — because neither the ChondroFiller injection nor the Liquid Cartilage surgical protocol is appropriate for established, widespread arthritis. Independent clinician-facing material is explicit that ChondroFiller is an acellular scaffold with limited published clinical evidence and is not positioned to regenerate normal hyaline cartilage across an arthritic joint.

That distinction depends on a structured assessment built around a clear history (for example, symptoms since a specific injury versus a gradual five-year decline), current functional limits (walking distance, stairs, sport), and measurable risk modifiers such as body mass index. High-quality imaging is typically central — MRI to characterise cartilage and bone-marrow change, CT where bony architecture matters (often in post-traumatic ankles), and ultrasound when image-guided injection planning is part of the pathway.

A cautious, evidence-led sequencing tends to follow a least-irreversible-first logic:

1. Optimise symptom management and mechanics: physiotherapy, load management, and — where relevant — alignment and movement strategy.
2. For symptomatic focal lesions, consider whether a scaffold-based approach is reasonable as a joint-preservation step. The ChondroFiller injection suits accessible lesions where surgery is not required; the Liquid Cartilage surgical protocol suits larger or load-bearing defects requiring arthroscopic preparation and biological augmentation. Keep expectations aligned with current evidence gaps.
3. Escalate to restorative surgery — cartilage transplantation, osteotomy — when lesion pattern and durability goals justify it.
4. Reserve fusion or joint replacement for clearly advanced disease; NHS guidance frames hip replacement around severe pain and disability that persist despite conservative measures and substantially affect quality of life and mobility.

London Cartilage Clinic at Harley Street, part of the MSK Doctors group, offers specialist joint-preservation assessment with access to both the ChondroFiller injection and, where appropriate, the Liquid Cartilage surgical protocol performed by Professor Lee, as well as onward pathways to cartilage repair procedures and arthroplasty. Earlier specialist assessment is often helpful when pain is limiting work, sleep, or sport, because the range of joint-preservation options tends to narrow once changes become widespread. If you are at that stage, a consultation to clarify the pattern of your joint damage and which pathway fits is a reasonable next step.

References: Cartilage Defect Treatment Using High-Density Autologous Chondrocyte Implantation (HD-ACI). Bioengineering, 2023, vol 10, no 9, p 1083.